Tags

Type your tag names separated by a space and hit enter

Assessment of quality of life of nasopharyngeal carcinoma patients with EORTC QLQ-C30 and H&N-35 modules.
Int J Radiat Oncol Biol Phys. 2005 Dec 01; 63(5):1347-53.IJ

Abstract

PURPOSE

The current study reports on long-term quality of life (QoL) status after conventional radiotherapy in 187 nasopharyngeal carcinoma patients from 14 centers in Turkey.

PATIENTS AND METHODS

Patients with the diagnosis of nasopharyngeal carcinoma, who were treated in 14 centers in Turkey with minimum 6 months of follow-up and were in complete remission, were asked to complete Turkish versions of EORTC QLQ-C30 questionnaire and the HN-35 module. Each center participated with the required clinical data that included age at diagnosis, gender, symptoms on admission, follow-up period, treatment modalities, radiotherapy dose, and AJCC 1997 tumor stage. Each patient's 33 QoL scores, which included function, global health status, and symptoms, were calculated as instructed in EORTC QLQ-C30 scoring manual. All of the scales and single-item measures range from 0 to 100. A high score represents a higher response level. Kruskal-Wallis and Mann-Whitney U nonparametric tests were used for comparisons.

RESULTS

One hundred eighty-seven patients with median age of 46 years (range, 16-79 years) participated and completed the questionnaires. Median follow-up time was 3.4 years (range, 6 months-24 years). All patients have received external-beam radiotherapy. Beside external-beam radiotherapy, 59 patients underwent brachytherapy boost, 70 patients received concomitant chemotherapy, and 95 patients received adjuvant/neoadjuvant chemotherapy. Most of the patients in the analysis (75%) were in advanced stage (Stage III, n = 85 [45.4%]; Stage IV, n = 55 [29%]). Mean global health status was calculated as 73. Parameters that increased global health status were male gender, early-stage disease, and less than 4-year follow-up (p < 0.05). Functional parameters were better in males and in early-stage disease. Factors that yielded better symptom scores were short interval after treatment (10 scores), male gender (7 scores), and lower radiation dose (6 scores). Neoadjuvant or adjuvant chemotherapy did not have any effect on QoL, whereas concomitant chemotherapy adversely affected 5 symptom scores.

CONCLUSION

Quality of life is adversely affected in our nasopharyngeal carcinoma patients treated with combined therapies. The factors that adversely affect quality of life are advanced tumor stage, female gender, and long-term follow-up. Further controlled studies to evaluate both preradiotherapy and postradiotherapy status are necessary to clarify the contribution of each treatment modality to QoL.

Authors+Show Affiliations

Turkish Oncology Group (TOG)--Head and Neck Cancer Working Party, Hacettepe University, Sihhiye, Ankara, Turkey. mcengiz@hacettepe.edu.trNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study

Language

eng

PubMed ID

16169671

Citation

Cengiz, Mustafa, et al. "Assessment of Quality of Life of Nasopharyngeal Carcinoma Patients With EORTC QLQ-C30 and H&N-35 Modules." International Journal of Radiation Oncology, Biology, Physics, vol. 63, no. 5, 2005, pp. 1347-53.
Cengiz M, Ozyar E, Esassolak M, et al. Assessment of quality of life of nasopharyngeal carcinoma patients with EORTC QLQ-C30 and H&N-35 modules. Int J Radiat Oncol Biol Phys. 2005;63(5):1347-53.
Cengiz, M., Ozyar, E., Esassolak, M., Altun, M., Akmansu, M., Sen, M., Uzel, O., Yavuz, A., Dalmaz, G., Uzal, C., Hiçsönmez, A., Sarihan, S., Kaplan, B., Atasoy, B. M., Ulutin, C., Abacioğlu, U., Demiral, A. N., & Hayran, M. (2005). Assessment of quality of life of nasopharyngeal carcinoma patients with EORTC QLQ-C30 and H&N-35 modules. International Journal of Radiation Oncology, Biology, Physics, 63(5), 1347-53.
Cengiz M, et al. Assessment of Quality of Life of Nasopharyngeal Carcinoma Patients With EORTC QLQ-C30 and H&N-35 Modules. Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1347-53. PubMed PMID: 16169671.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Assessment of quality of life of nasopharyngeal carcinoma patients with EORTC QLQ-C30 and H&N-35 modules. AU - Cengiz,Mustafa, AU - Ozyar,Enis, AU - Esassolak,Mustafa, AU - Altun,Musa, AU - Akmansu,Müge, AU - Sen,Mehmet, AU - Uzel,Omer, AU - Yavuz,Aydin, AU - Dalmaz,Gamze, AU - Uzal,Cem, AU - Hiçsönmez,Ayşe, AU - Sarihan,Süreyya, AU - Kaplan,Bünyamin, AU - Atasoy,Beste Melek, AU - Ulutin,Cüneyt, AU - Abacioğlu,Ufuk, AU - Demiral,Ayşe Nur, AU - Hayran,Mutlu, Y1 - 2005/09/19/ PY - 2005/04/22/received PY - 2005/05/31/revised PY - 2005/05/31/accepted PY - 2005/9/20/pubmed PY - 2006/1/10/medline PY - 2005/9/20/entrez SP - 1347 EP - 53 JF - International journal of radiation oncology, biology, physics JO - Int. J. Radiat. Oncol. Biol. Phys. VL - 63 IS - 5 N2 - PURPOSE: The current study reports on long-term quality of life (QoL) status after conventional radiotherapy in 187 nasopharyngeal carcinoma patients from 14 centers in Turkey. PATIENTS AND METHODS: Patients with the diagnosis of nasopharyngeal carcinoma, who were treated in 14 centers in Turkey with minimum 6 months of follow-up and were in complete remission, were asked to complete Turkish versions of EORTC QLQ-C30 questionnaire and the HN-35 module. Each center participated with the required clinical data that included age at diagnosis, gender, symptoms on admission, follow-up period, treatment modalities, radiotherapy dose, and AJCC 1997 tumor stage. Each patient's 33 QoL scores, which included function, global health status, and symptoms, were calculated as instructed in EORTC QLQ-C30 scoring manual. All of the scales and single-item measures range from 0 to 100. A high score represents a higher response level. Kruskal-Wallis and Mann-Whitney U nonparametric tests were used for comparisons. RESULTS: One hundred eighty-seven patients with median age of 46 years (range, 16-79 years) participated and completed the questionnaires. Median follow-up time was 3.4 years (range, 6 months-24 years). All patients have received external-beam radiotherapy. Beside external-beam radiotherapy, 59 patients underwent brachytherapy boost, 70 patients received concomitant chemotherapy, and 95 patients received adjuvant/neoadjuvant chemotherapy. Most of the patients in the analysis (75%) were in advanced stage (Stage III, n = 85 [45.4%]; Stage IV, n = 55 [29%]). Mean global health status was calculated as 73. Parameters that increased global health status were male gender, early-stage disease, and less than 4-year follow-up (p < 0.05). Functional parameters were better in males and in early-stage disease. Factors that yielded better symptom scores were short interval after treatment (10 scores), male gender (7 scores), and lower radiation dose (6 scores). Neoadjuvant or adjuvant chemotherapy did not have any effect on QoL, whereas concomitant chemotherapy adversely affected 5 symptom scores. CONCLUSION: Quality of life is adversely affected in our nasopharyngeal carcinoma patients treated with combined therapies. The factors that adversely affect quality of life are advanced tumor stage, female gender, and long-term follow-up. Further controlled studies to evaluate both preradiotherapy and postradiotherapy status are necessary to clarify the contribution of each treatment modality to QoL. SN - 0360-3016 UR - https://www.unboundmedicine.com/medline/citation/16169671/Assessment_of_quality_of_life_of_nasopharyngeal_carcinoma_patients_with_EORTC_QLQ_C30_and_H&N_35_modules_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0360-3016(05)01004-7 DB - PRIME DP - Unbound Medicine ER -